Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06550583

Screening for Early Cervical Cancer Detection

This study is to audit results and adherence to Cervical Screening program before and after the implementing awareness of the WHO guidelines of screening among the multidisciplinary healthcare workers and patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

About this study

Cervical cancer screening is the asymptomatic detection of pre-cancer and cancer in women at risk, with at least one screening suggested for women aged 30-49 years. According to the World Health Survey (2015), 19% of eligible women in developing countries and 63% of those in developed nations had their cervical cancer screening done using a Pap smear or visual inspection with acetic acid (VIA).

According to latest estimates by World Health Organization (WHO), in Egypt, 866 women are diagnosed with cervical cancer every year and 373 die from the disease. Cervical cancer is the 13th most common cancer in women in Egypt and the 10th most common cancer in women aged between 15 to 44 years . Statistics from Egyptian studies provide pre invasive cervical lesion incidence levels of 0.3 % to 0.5 % .

The human papillomavirus (HPV) is one of the most significant risk factors for cervical cancer. HPV can be transmitted through sexual contact, including vaginal or oral sex with an infected person. HPV has more than 100 strains, of which HPV16 and HPV18 account for about 70% of invasive cervical cancers

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women 20-60 years.
  • Sexually active.
  • Fulfilling Cervical Check's eligibility criteria for screening at the time of the audit https://www.cervicalcheck.ie/_fileupload/File/Eligibility%20Framework.pdf

Exclusion criteria

Patient who had underwent to total hysterectomy.

  • Pregnant or postpartum or post abortive patients
  • Patient having any history of treatment for cervical dysplasia.
  • Immunocompromised patients.

Treatment and study plan

Pap smear /Test

Diagnostic Test

Patients will be placed in the lithotomy position, and a sterile bivalve speculum will be inserted into the vagina.

  • A sample will be taken from the ectocervix by rotating a wooden Ayre spatula 360°. The sample will be quickly smeared onto a labeled glass slide and fixed with 95% ethyl alcohol in a jar to be sent to the Department of Pathology for cytopathological examination

Primary outcomes

  1. Screening clinic in Women & Children Hospital

    Time frame: Baseline

    All women undergo Pap smear test according to inclusion criteria and will be adherence to screening program protocol

Secondary outcomes

  1. Via test

    Time frame: baseline

    Via test will be done to all patients come to screening clinic and Adherence to screening program protocol

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

A Clinical Audit on Screening Program for Early Cervical Cancer Detection.

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Aug 13, 2024
Registry last updated
Aug 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.